2018 Gastroesophageal Reflux Disease (GERD) Drug Development- Pipeline Analysis Report

May 2018 | | ID: 294FAE41126EN
VPAResearch

Abstracts

With an estimated 25 million people being affected by Gastroesophageal reflux disease (GERD) in the US, it is considered as one of the most common GI Disorders. GERD causes stomach contents regurgitate into the esophagus, causing damage to esophagus.

Around 30 companies and universities are focusing on developing treatment options for Gastroesophageal Reflux Disease (GERD).

To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Gastroesophageal Reflux Disease (GERD) pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Gastroesophageal Reflux Disease (GERD) pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Gastroesophageal Reflux Disease (GERD) pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Contents

1 TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2 GASTROESOPHAGEAL REFLUX DISEASE (GERD) PIPELINE ANALYSIS

2.1 Disease and Pipeline Overview
2.2 Gastroesophageal Reflux Disease (GERD) Pipeline Snapshot
2.3 Gastroesophageal Reflux Disease (GERD) Pipeline by Phase
2.4 Gastroesophageal Reflux Disease (GERD) Pipeline by Company
2.5 Gastroesophageal Reflux Disease (GERD) Pipeline by Mechanism of Action

3 GASTROESOPHAGEAL REFLUX DISEASE (GERD)- COMPANY WISE PIPELINE ANALYSIS

Cancer Advances Inc
CJ HealthCare
Daewoong Pharmaceutical Co
Effexus Pharmaceutical
Eisai Co Ltd
Il-Yang Pharm.Co.,Ltd
Ironwood Pharmaceuticals
Jeil Pharmaceutical Co Ltd
Jiangsu Aosaikang Pharmaceutical
Mitsubishi Pharma Corporation
New Haven Pharmaceuticals
Pfizer
RaQualia Pharma Inc
Renexxion LLC
Rottapharm
Takeda Pharmaceutical Co
Trio Medicines Ltd
Yooyoung Pharm Co Ltd
Yuyu Pharma Inc

4 GASTROESOPHAGEAL REFLUX DISEASE (GERD) R&D PIPELINE SNAPSHOTS

Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details

5 RECENT DEVELOPMENTS IN GASTROESOPHAGEAL REFLUX DISEASE (GERD) PIPELINE

6 APPENDIX

6.1 About VPA Research
6.2 Sources and Research Methodology

List Of Figures

LIST OF FIGURES

Figure 1: Gastroesophageal Reflux Disease (GERD) Pipeline by Phase, H1- 2018
Figure 2: Gastroesophageal Reflux Disease (GERD) Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Gastroesophageal Reflux Disease (GERD) Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018

List Of Tables

LIST OF TABLES

Table 1: Gastroesophageal Reflux Disease (GERD) Pipeline by Phase, H1- 2018
Table 2: Gastroesophageal Reflux Disease (GERD) Pipeline by Companies, H1- 2018
Table 3: Gastroesophageal Reflux Disease (GERD) Pipeline by Mechanism of Action, H1- 2018
Table 4: Cancer Advances Inc Gastroesophageal Reflux Disease Pipeline, May 2018
Table 5: CJ HealthCare Gastroesophageal Reflux Disease Pipeline, May 2018
Table 6: Daewoong Pharmaceutical Co Gastroesophageal Reflux Disease Pipeline, May 2018
Table 7: Effexus Pharmaceutical Gastroesophageal Reflux Disease Pipeline, May 2018
Table 8: Eisai Co Ltd Gastroesophageal Reflux Disease Pipeline, May 2018
Table 9: Eisai Co Ltd Gastroesophageal Reflux Disease Pipeline, May 2018
Table 10: Il-Yang Pharm.Co.,Ltd Gastroesophageal Reflux Disease Pipeline, May 2018
Table 11: Ironwood Pharmaceuticals Gastroesophageal Reflux Disease Pipeline, May 2018
Table 12: Jeil Pharmaceutical Co Ltd Gastroesophageal Reflux Disease Pipeline, May 2018
Table 13: Jiangsu Aosaikang Pharmaceutical Gastroesophageal Reflux Disease Pipeline, May 2018
Table 14: Mitsubishi Pharma Corporation Gastroesophageal Reflux Disease Pipeline, May 2018
Table 15: New Haven Pharmaceuticals Gastroesophageal Reflux Disease Pipeline, May 2018
Table 16: Pfizer Gastroesophageal Reflux Disease Pipeline, May 2018
Table 17: RaQualia Pharma Inc Gastroesophageal Reflux Disease Pipeline, May 2018
Table 18: Renexxion LLC Gastroesophageal Reflux Disease Pipeline, May 2018
Table 19: Rottapharm Gastroesophageal Reflux Disease Pipeline, May 2018
Table 20: Takeda Pharmaceutical Co Gastroesophageal Reflux Disease Pipeline, May 2018
Table 21: Trio Medicines Ltd Gastroesophageal Reflux Disease Pipeline, May 2018
Table 22: Yooyoung Pharm Co Ltd Gastroesophageal Reflux Disease Pipeline, May 2018